GSK turns to R&D jobs for savings
GlaxoSmithKline announced plans to cut R&D employment in the U.K. and U.S. by 850 positions, or about 6 percent of its global R&D staff of 15,000, as part of an ongoing restructuring program. In July, the company announced it is creating small drug performance units, which will operate within its Centers of Excellence for Drug Discovery. The centers focus on particular therapeutic areas; the new units, consisting of five to 80 scientists, concentrate on specific biological pathways and will compete for funding (1"The Pink Sheet," July 28, 2008, p. 10)
You may also be interested in...
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.